



dr. van haeringen laboratorium b.v.

a VHLGenetics company

VAN ROOIJ
Rue des Combattants d'Havannes
7531 Havannes
BELGIUM
Customer number 127764

Through: Zoolyx NV
Groene Weg 17 17
BE-9320 EREMBODEGEM
BELGIUM

Analysis Certificate

Animal data

Name: SILKE DU CHEMIN DES CAVALIERS
Date of birth: 21.04.2020
Sexe: Female
Reg. nr.: 250269500825397
Breed: Beagle

Sample data

VHL_ID: H592194
Test ID-nr: 580323 1
Material: Swab

H364 - Hypocatalasia - Date of test: 19.06.2023

Testresult: NORMAL

H366 - IGS (Selective Cobalamin Malabsorption) 1 - Date of test: 19.06.2023

Testresult: NORMAL

H413 - Cerebellar abiotrophy - Date of test: 19.06.2023

Testresult: NORMAL

H424 - Musladin-Lueke syndrome - Date of test: 19.06.2023

Testresult: NORMAL

H430 - Osteogenesis imperfect Beagle - Date of test: 19.06.2023

Testresult: NORMAL

H435 - Factor VII deficiency - Date of test: 19.06.2023

Testresult: NORMAL

H455 - Pyruvate Kinase Deficiency (PKDef) - Beagle - Date of test: 19.06.2023

Testresult: NORMAL

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were accepted at the time of purchase. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.



dr. van haeringen laboratorium b.v.
a VHLGenetics company

H496 - Glaucoma (POAG) - Date of test: 19.06.2023

Testresult: NORMAL

H811 - Hyperuricemia (HUU) - Date of test: 19.06.2023

Testresult: NORMAL

H919 - Hioplaxity 1 - Date of test: 19.06.2023

Testresult: HL/HL

H421 - Hioplaxity 2 - Date of test: 19.06.2023

Testresult: HL/HL

H346 - Chondrodystrophy and Intervertebral Disc Disease - Date of test: 19.06.2023

Testresult: AFFECTED

H468 - Lafora Disease - Date of test: 23.06.2023

Testresult: NORMAL

D. Mioch, MSc Veterinary Medicine
CEO

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were accepted at the time of purchase. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.

(Certificate nr: H130533/Date of issue: 23.06.2023)

page 2 of 5



H364 - Hypocatalasia

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H366 - IGS (Selective Cobalamin Malabsorption) 1

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H413 - Cerebellar abiotrophy

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H424 - Musladin-Lueke syndrome

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H430 - Osteogenesis imperfect Beagle

This genetic factor was detected as a heterozygous mutation in a severely affected proband which indicates a dominant mode of inheritance. This is in agreement with the homozygous human variant of Osteogenesis imperfecta, where in the vast majority of instances, the phenotype results from heterozygosity for mutations in one of the genes that encode chains of type I collagen.

However, as the number of cases analysed in dogs is currently low, this conclusion contains a certain degree of uncertainty.

H435 - Factor VII deficiency

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were accepted at the time of purchase. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.



dr. van haeringen laboratorium b.v.

a VHLGenetics company

the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.
CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.
AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H455 - Pyruvate Kinase Deficiency (PKDef) - Beagle

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.
CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.
AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H496 - Glaucoma (POAG)

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.
CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.
AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H811 - Hyperuricemia (HUU)

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.
CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.
AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H919 - Hip laxity 1

The disease is of multifactorial origin, which means that the symptoms are a combination of genetic factors as well as the environment.

This marker is part of a panel of genetic factors influencing hip laxity. For each genetic factor of a multifactorial disease, the desirable genetic variant is indicated as 'N/N'. Animals carrying one copy of the undesirable genetic variant are indicated as 'N/HL', whereas animals carrying two copies of the undesirable genetic variant are indicated as 'HL/HL'.

H421 - Hip laxity 2

The disease is of multifactorial origin, which means that the symptoms are a combination of genetic factors as well as the environment.

This marker is part of a panel of genetic factors influencing hip laxity. For each genetic factor of a multifactorial disease, the desirable genetic variant is indicated as 'N/N'. Animals carrying one copy of the undesirable genetic variant are indicated as 'N/HL', whereas animals carrying two copies of the undesirable genetic variant are indicated as 'HL/HL'.

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were accepted at the time of purchase. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.



dr. van haeringen laboratorium b.v.

a VHLGenetics company

H346 - Chondrodystrophy and Intervertebral Disc Disease

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will most likely develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

H468 - Lafora Disease

Explanation about the result:

NORMAL: The animal has two normal alleles and is therefore not affected by this specific variant. The animal will not develop the described clinical features due to this variant. When used in breeding, a healthy allele will be passed to all offspring.

CARRIER: The animal is a carrier; it has one normal and one affected allele. The animal will not develop the described clinical features due to this variant. In breeding, there is a 50% chance for each offspring that it will receive an affected allele.

AFFECTED: The animal is affected; it has two affected alleles. The animal will most likely develop the described clinical features due to this variant. When used in breeding, all offspring will receive an affected allele.

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were accepted at the time of purchase. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.